All In Biotech

Drug Trial Radar · NCT00095654

The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial

Last checked: Nov 20, 2026Latest source record: Nov 10, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,000

Actual

Start

Jul 2001

Primary completion

Not stated

Study completion Oct 2006

Sponsor

Lead sponsor
Gerstein, Hertzel, MDIndividual
Sponsor type
Individual
Collaborators
Canadian Institutes of Health Research (CIHR); Aventis Pharmaceuticals; GlaxoSmithKline; King Pharmaceuticals is now a wholly owned subsidiary of Pfizer; Wyeth is now a wholly owned subsidiary of Pfizer
First posted
Nov 8, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double
Primary purpose
Prevention
Who can join
All sexes, from 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if ramipril and/or rosiglitazone prevent the onset of type 2 diabetes.

Conditions

  • Impaired Glucose Tolerance
  • Cardiovascular Disease
  • Glucose Metabolism Disorders

Interventions

  • RamiprilDrug

  • RosiglitazoneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. diabetes
  2. death

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.